(firstQuint)The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated).

 Influenza Virus Vaccine (Split Virion, Inactivated) that do not contains Preservative.

 HA contents 151/2g/0.

5ml per dose includ H1N1,H3N2 and B.

 Inactivated Split Influenza Vaccine was manufactured by Sanofi Pasteur HA contents 151/2g/0.

5ml per dose includ H1N1,H3N2 and B.

 This is a randomized, blind phase 3 clinical trial.

 Total 1200 adults (above ages 36 months ) were selected, randomized to two groups [Influenza Virus Vaccine (Split Virion, Inactivated) and Inactivated Split Influenza Vaccine , each group n=600], adults in each group will be vaccinated with one dose of either Influenza Virus Vaccine (Split Virion, Inactivated) or Sanof IVV respectively.

.

 The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)@highlight

The purpose of this study is to evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated) that do not contains Preservative .

